Initial Antiarrhythmic Drug Therapy During Resuscitation from Sudden Cardiac Death: A Time for a Fundamental Change in Strategy?

Abstract

References

Julian DG , Valentine PA , Miller GG Disturbances of rate, rhythm and conduction in acute myocardial infarction . Am J Med 37:915, 1964

Pantridge JF Emergency treatment of cardiac arrhythmias in myocardial infarction , in Scott DB , Julian DG (eds). Lidocaine in the Treatment of Ventricular Arrhythmias . Edinburgh, Scotland , E & S Livingstone, 1971 pp. 77-81

Cobb LA , Hallstrom AP

Community-based cardiopulmonary resuscitation: What have we learned?

Ann NY Acad Sci 382:333, 1982

Bayes de Luna A. , Coumel P. , Leclerq JF Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 137 patients. Am Heart J 117:151, 1989

Emergency Cardiac Care Committee and Subcommittees AHA. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. JAMA 268:222, 1992

Herlitz J. , Ekstrom L. , Wennerblom B. , et al. Lidocaine in out-of-hospital ventricular fibrillation: Does it improve survival? Resuscitation 33:199, 1997

Carden NJ , Steinhaus JE Lidocaine in cardiac resuscitation from ventricular fibrillation. Circ Res 4:680, 1956

Lazzara R. , Hope RR , El-Sherif N. Effects of lidocaine on hypoxic and ischemic cardiac cells. Am J Cardiol 41:872, 1978

Borer JS , Harrison LA , Kent KM Beneficial effect of lidocaine on ventricular electrical stability and spontaneous ventricular fibrillation during experimental myocardial infarction. Am J Cardiol 137:860, 1976

10.

Spear JF , Moore EN , Gerstenblith G. Effect of lidocaine on the ventricular fibrillation threshold in the dog during acute ischemia and premature ventricular contractions. Circulation 46:65, 1976

11.

Hanyok JJ , Chow Mss , Kluger J. , et al. Antifibrillatory effects of high dose bretylium and a lidocaine-bretylium combination during cardiopulmonary resuscitation. Crit Care Med 16:691, 1988

12.

Lie RI , Wellens HJ , Van Capellie FJ. Lidocaine in the prevention of primary ventricular fibrillation: A double-blind, randomized study of 212 consecutive patients. N Engl J Med 291:1325, 1974

13.

Weaver WD , Fahrenbruch CE , Johnson DD , et al. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation 82:2027, 1990

14.

Furberg CD Effect of antiarrhythmic drugs on mortality after myocardial infarction . Am J Cardiol 53:23C, 1983

15.

MacMahon S. , Collins R. , Peto R. , et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction: An overview of results from randomized controlled clinical trials. JAMA 260:1910, 1988

16.

Hine LK , Laird N. , Hewitt P. , et al. Meta-analysis evidence against prophylactic lidocaine in acute myocardial infarction. Arch Intern Med 149:2694, 1989

17.

Singh BN

Routine prophylactic administration in acute myocardial infarction. An idea whose time is all but gone?

Circulation 86:1033, 1992

18.

Antman EM , Berlin JA Declining incidence of ventricular fibrillation in myocardial infarction: Implications for the prophylactic use of lidocaine. Circulation 86:764, 1992

19.

The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of flecainide and encainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406, 1989

20.

Haynes RE , Chinn TL , Copass MK , et al. Comparison of bretylium tosylate and lidocaine in management of out-of-hospital ventricular fibrillation: A randomized clinical trial. Am J Cardiol 48:353, 1981

21.

Olson DW , Thompson BM , Darin JC , et al. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann Emerg Med 113:807, 1984

22.

Singh BN Antiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of cardiac rhythm. Am J Cardiol 81:3D, 1998

23.

Singh BN Current antiarrhythmic drugs: An overview of mechanisms of action and clinical utility action and potential clinical utility. J Cardiovasc Electrophysiol 10:283, 1999

24.

Yusuf S. , Peto R. , Lewis J. , et al. Beta-blockade during myocardial infarction: an overview of randomized trials. Prog Cardiovasc Dis 27:335, 1985

25.

Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707, 1982

26.

The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 6:199, 1985

27.

ISIS-1 Collaborative Group.

Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1 (First International Study of Infarct Survival)

Lancet 1:921, 1988

28.

Kendall MJ , Lynch KP , Hjalmarson A. , et al. Beta-blockers and sudden cardiac death. Ann Intern Med 123:358, 1995

29.

Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol; 80:35J-39J, 1997

30.

Norris RM , Barnaby PF , Brown MA , et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 2:883-886, 1984

31.

Ryden L. , Arciniego R. , Arnonan K. A double-blind trial of metoprolol in acute myocardial infarction. Effects of ventricular tachyarrhythmias. N Engl J Med 308:614, 1983

32.

Schwartz PJ The idiopathic long QT interval syndrome: Progress and questions. Am Heart J 109:399, 1985

33.

Hallstrom AP , Cobb LA , Yu BH , et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 68:1025, 1991

34.

Chadda K. , Goldstein S. , Byington R. , et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73:5013, 1986

35.

Teerlink JR , Bassie BM Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol 84:94R, 1999

36.

Packer M. , Colucci WS , Sackner-Bernstein JD , et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation 94:2793, 1996

37.

Packer M. , Bristow MR , Cohn JN The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1334:1349, 1996

38.

MERIT-HEFT Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001, 1999

39.

CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): A randomized trial . Lancet 353:9, 1999

40.

Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of cardevilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349:375, 1997

41.

Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92:212, 1995

42.

Singh B. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent . Am J Cardiol 78:41, 1996

43.

Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors . Br J Pharmacol. 39:668-674, 1970

44.

Amiodarone Trials Meta-Analysis Investigators. The effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual patient data on 6500 patients from randomised trials. Lancet 350:1417, 1997

45.

Boutitie F. , Boissel JP , Connolly SJ , et al. Amiodarone Interaction with β-Blockers: Analysis of the merged EMIAT and CAMIAT databases. Circulation 99:2268, 1999

46.

Julian DG , Camm AJ , Franglin G. , et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT . Lancet 349:667, 1997

47.

Cairns JA , Connolly SJ , Roberts RJ , et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT . Lancet 349:675, 1997

48.

Guidelines for advanced life support: A statement by the Advanced Life Support Working Party of the European Resuscitation Council, 1992. Resuscitation 24:111, 1992

49.

Scheinman MM , Levine JH , Cannom DS , et al. Intravenous Amiodarone Multicenter Investigative Group. Dose ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias . Circulation 92:3264, 1995

50.

Kowey PR , Levine JH , Herre JM , et al. Intravenous Amiodarone Multicenter Investigative Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 92:3255, 1995

51.

Kudenchuk PJ , Cobb LA , Copass MK , et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 341:871-8, 1999